Abstract
BackgroundThe expression of Coiled-Coil Domain Containing 134(CCDC134) is up-regulated in different pan-cancer species. However, its prognostic value and correlation with immune infiltration in breast cancer are unclear. Therefore, we evaluated the prognostic role of CCDC134 in breast cancer and its correlation with immune invasion.MethodsWe downloaded the transcription profile of CCDC134 between breast cancer and normal tissues from the Cancer Genome Atlas (TCGA). CCDC134 protein expression was assessed by the Clinical Proteomic Cancer Analysis Consortium (CPTAC) and the Human Protein Atlas. Gene set enrichment analysis (GSEA) was also used for pathway analysis. Receiver operating characteristic (ROC) curve was used to differentiate breast cancer from adjacent normal tissues. Kaplan-Meier method was used to evaluate the effect of CCDC134 on survival rate. The protein-protein interaction (PPI) network is built from STRING. Function expansion analysis is performed using the ClusterProfiler package. Through tumor Immune Estimation Resource (TIMER) and tumor Immune System Interaction database (TISIDB) to determine the relationship between CCDC134 expression level and immune infiltration. CTD database is used to predict drugs that inhibit CCDC134 and PubChem database is used to determine the molecular structure of identified drugs.ResultsThe expression of CCDC134 in breast cancer tissues was significantly higher than that of CCDC134 mRNA expression in adjacent normal tissues. ROC curve analysis showed that the AUC value of CCDC134 was 0.663. Kaplan-meier survival analysis showed that patients with high CCDC134 had a lower prognosis (57.27 months vs 36.96 months, P = 2.0E-6). Correlation analysis showed that CCDC134 mRNA expression was associated with tumor purity immune invasion. In addition, CTD database analysis identified abrine, Benzo (A) Pyrene, bisphenol A, Soman, Sunitinib, Tetrachloroethylene, Valproic Acid as seven targeted therapy drugs that may be effective treatments for seven targeted therapeutics. It may be an effective treatment for inhibiting CCDC134.ConclusionIn breast cancer, upregulated CCDC134 is significantly associated with lower survival and immune infiltrates invasion. Our study suggests that CCDC134 can serve as a biomarker of poor prognosis and a potential immunotherapy target in breast cancer. Seven drugs with significant potential to inhibit CCDC134 were identified.
Highlights
Breast cancer (BC) has overtaken lung cancer as the most common cancer worldwide and is the most common cancer in women [1]
The results showed that CCDC134 protein expression in breast cancer was significantly higher than that in normal tissues (Figure 2C)
E, Human Protein Atlas (HPA) immunohistochemical staining showed up-regulation of CCDC134 protein expression in breast cancer tissues. These results showed that both mRNA and protein expression of CCDC134 were up-regulated in breast cancer tissues
Summary
Breast cancer (BC) has overtaken lung cancer as the most common cancer worldwide and is the most common cancer in women [1]. Studies have shown that the prognosis of breast cancer is influenced by a variety of clinical factors [10], such as age, tumor size, histological grade, lymphatic infiltration, number of lymph node metastases, hormone receptor status, Her-2 status, and positive margins. Due to the complexity of the onset of breast cancer and the heterogeneity of tumors, many prognostic markers have been found, the prediction efficiency is still inadequate [11, 12]. It is necessary to build a new breast cancer risk prediction model to improve the treatment and prognosis of breast cancer patients. Its prognostic value and correlation with immune infiltration in breast cancer are unclear. We evaluated the prognostic role of CCDC134 in breast cancer and its correlation with immune invasion
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
